Ost-müük GTX Inc - ONCT CFD
Lisa lemmikuks- Kokkuvõte
- Ajaloolised andmed
- Sündmused
- Tuluaruanne
- Bilanss
- Rahavood
- Omand
Hinnavahe | 0.05 | ||||||||
Pika positsiooni ööpäeva tasu
Long position overnight fee
Mine platvormile | -0.025457% | ||||||||
Lühikese positsiooni ööpäeva tasu
Short position overnight fee
Mine platvormile | 0.003235% | ||||||||
Ööpäeva tasu aeg | 21:00 (UTC) | ||||||||
Min kauplemise kogus | 1 | ||||||||
Valuuta | USD | ||||||||
Tagatis | 20% | ||||||||
Aktsiabörs | United States of America | ||||||||
Kauplemise vahendustasu | 0% |
*Information provided by Capital.com
Oncternal Therapeutics Inc ESG Risk Ratings
‘C’ score indicates satisfactory relative ESG performance and moderate degree of transparency in reporting material ESG data publicly.
Eelmine sulgemine* | 0.75 |
Avatud* | 0.77 |
Aastane muutus* | -42.54% |
Päeva ulatus* | 0.74 - 0.78 |
52 nädala ulatus | 0.26-1.87 |
Keskmine maht (10 päeva) | 171.33K |
Keskmine maht (3 kuud) | 11.74M |
Turukapitalisatsioon | 17.66M |
P/E suhtarv | -100.00K |
Ringluses olevad aktsiad | 58.73M |
Tulu | 947.00K |
EPS | -0.84 |
Dividendid (% kasumist) | N/A |
Beeta | 1.44 |
Järgmine tuluaruande kuupäev | Aug 7, 2023 |
Kõigi andmete allikas on Refinitiv, välja arvatud tärniga märgitud, kus *-ga andmed on esitanud Capital.com
- Last Week
- Last Month
- Last Year
- Last two Years
- Max
- Daily
- Weekly
- Monthly
Date | Close | Sulgemishind | Change (%) | Avamishind | High | Low |
---|---|---|---|---|---|---|
Apr 3, 2023 | 0.77 | 0.00 | 0.00% | 0.77 | 0.78 | 0.74 |
Mar 31, 2023 | 0.75 | 0.00 | 0.00% | 0.75 | 0.77 | 0.75 |
Mar 30, 2023 | 0.78 | 0.03 | 4.00% | 0.75 | 0.79 | 0.73 |
Mar 29, 2023 | 0.73 | 0.00 | 0.00% | 0.73 | 0.75 | 0.72 |
Mar 28, 2023 | 0.75 | 0.01 | 1.35% | 0.74 | 0.76 | 0.72 |
Mar 27, 2023 | 0.77 | -0.09 | -10.47% | 0.86 | 0.86 | 0.74 |
Mar 24, 2023 | 0.83 | 0.00 | 0.00% | 0.83 | 0.85 | 0.82 |
Mar 23, 2023 | 0.85 | 0.15 | 21.43% | 0.70 | 0.85 | 0.70 |
Mar 22, 2023 | 0.68 | 0.06 | 9.68% | 0.62 | 0.69 | 0.61 |
Mar 21, 2023 | 0.60 | -0.05 | -7.69% | 0.65 | 0.66 | 0.57 |
Mar 20, 2023 | 0.65 | -0.01 | -1.52% | 0.66 | 0.69 | 0.61 |
Mar 17, 2023 | 0.66 | -0.04 | -5.71% | 0.70 | 0.70 | 0.66 |
Mar 16, 2023 | 0.69 | 0.01 | 1.47% | 0.68 | 0.69 | 0.68 |
Mar 15, 2023 | 0.70 | 0.01 | 1.45% | 0.69 | 0.73 | 0.67 |
Mar 14, 2023 | 0.71 | -0.08 | -10.13% | 0.79 | 0.81 | 0.65 |
Mar 13, 2023 | 0.77 | 0.04 | 5.48% | 0.73 | 0.79 | 0.73 |
Mar 10, 2023 | 0.72 | -0.07 | -8.86% | 0.79 | 0.81 | 0.69 |
Mar 9, 2023 | 0.86 | -0.01 | -1.15% | 0.87 | 0.88 | 0.85 |
Mar 8, 2023 | 0.87 | -0.02 | -2.25% | 0.89 | 0.89 | 0.86 |
Mar 7, 2023 | 0.89 | -0.03 | -3.26% | 0.92 | 0.92 | 0.87 |
GTX Inc Events
Kellaaeg (UTC) (UTC) | Riik | Sündmus |
---|---|---|
Friday, June 16, 2023 | ||
Kellaaeg (UTC) (UTC) 15:00 | Riik US
| Sündmus Oncternal Therapeutics Inc Annual Shareholders Meeting Oncternal Therapeutics Inc Annual Shareholders MeetingForecast -Previous - |
Wednesday, June 28, 2023 | ||
Kellaaeg (UTC) (UTC) 15:00 | Riik US
| Sündmus Oncternal Therapeutics Inc Annual Shareholders Meeting Oncternal Therapeutics Inc Annual Shareholders MeetingForecast -Previous - |
Monday, August 7, 2023 | ||
Kellaaeg (UTC) (UTC) 20:00 | Riik US
| Sündmus Q2 2023 Oncternal Therapeutics Inc Earnings Release Q2 2023 Oncternal Therapeutics Inc Earnings ReleaseForecast -Previous - |
Wednesday, November 1, 2023 | ||
Kellaaeg (UTC) (UTC) 10:59 | Riik US
| Sündmus Q3 2023 Oncternal Therapeutics Inc Earnings Release Q3 2023 Oncternal Therapeutics Inc Earnings ReleaseForecast -Previous - |
- Aastas
- Kvartalis
2022 | 2021 | 2020 | 2019 | 2018 | |
---|---|---|---|---|---|
Kogutulu | 1.49 | 4.315 | 3.375 | 2.425 | 0 |
Kogu tegevuskulu | 46.437 | 35.681 | 20.917 | 35.533 | 39.059 |
Müük/Üldine/admin kulud, kokku | 13.457 | 11.595 | 8.373 | 7.286 | 9.39 |
Uuringud ja arendus | 32.98 | 24.086 | 12.544 | 28.247 | 29.669 |
Depreciation / Amortization | |||||
Tulud majandustegevusest | -44.947 | -31.366 | -17.542 | -33.108 | -39.059 |
Muud, neto | 0 | 0.301 | -1.268 | 0.641 | |
Netotulu enne makse | -44.17 | -31.333 | -17.225 | -34.188 | -38.418 |
Netotulu pärast makse | -44.17 | -31.333 | -17.225 | -34.188 | -38.418 |
Netotulu enne erikulusid | -44.17 | -31.333 | -17.225 | -34.188 | -38.418 |
Netotulu | -44.17 | -31.333 | -17.225 | -34.188 | -38.418 |
Arvestatav tulu, v a erikulud | -44.17 | -31.333 | -17.225 | -34.188 | -38.418 |
Arvestatav tulu, koos erikuludega | -44.17 | -31.333 | -17.225 | -34.188 | -38.418 |
Jaotamisele kuuluv netotulu | -44.17 | -31.333 | -17.225 | -34.188 | -38.418 |
Keskmine jaotamisele kuuluv aktsia kohta | 52.594 | 49.321 | 20.305 | 10.329 | 163.42 |
Jaotatav EPS, v a erakorralised kulud | -0.83983 | -0.63529 | -0.84831 | -3.3099 | -0.23509 |
Jaotamisele kuuluv normaal-EPS | -0.83983 | -0.63529 | -0.84831 | -3.3099 | -0.23509 |
Jaotuse korrigeerimine | |||||
Tulu | 1.49 | 4.315 | 3.375 | 2.425 | |
Intressitulud (kulu), muud tulud, neto | 0.777 | 0.033 | 0.016 | 0.188 |
Mar 2023 | Dec 2022 | Sep 2022 | Jun 2022 | Mar 2022 | |
---|---|---|---|---|---|
Kogutulu | 0.203 | 0.171 | 0.382 | 0.191 | 0.746 |
Tulu | 0.203 | 0.171 | 0.382 | 0.191 | 0.746 |
Kogu tegevuskulu | 12.346 | 12.086 | 11.707 | 11.986 | 10.658 |
Müük/Üldine/admin kulud, kokku | 3.315 | 3.288 | 3.265 | 3.225 | 3.679 |
Uuringud ja arendus | 9.031 | 8.798 | 8.442 | 8.761 | 6.979 |
Tulud majandustegevusest | -12.143 | -11.915 | -11.325 | -11.795 | -9.912 |
Intressitulud (kulu), muud tulud, neto | 0.656 | 0.515 | 0.2 | 0.054 | 0.008 |
Netotulu enne makse | -11.487 | -11.4 | -11.125 | -11.741 | -9.904 |
Netotulu pärast makse | -11.487 | -11.4 | -11.125 | -11.741 | -9.904 |
Netotulu enne erikulusid | -11.487 | -11.4 | -11.125 | -11.741 | -9.904 |
Netotulu | -11.487 | -11.4 | -11.125 | -11.741 | -9.904 |
Arvestatav tulu, v a erikulud | -11.487 | -11.4 | -11.125 | -11.741 | -9.904 |
Arvestatav tulu, koos erikuludega | -11.487 | -11.4 | -11.125 | -11.741 | -9.904 |
Jaotamisele kuuluv netotulu | -11.487 | -11.4 | -11.125 | -11.741 | -9.904 |
Keskmine jaotamisele kuuluv aktsia kohta | 58.522 | 56.62 | 54.212 | 50.064 | 49.429 |
Jaotatav EPS, v a erakorralised kulud | -0.19629 | -0.20134 | -0.20521 | -0.23452 | -0.20037 |
Dividends per Share - Common Stock Primary Issue | 0 | 0 | 0 | 0 | |
Jaotamisele kuuluv normaal-EPS | -0.19629 | -0.20134 | -0.20521 | -0.23452 | -0.20037 |
Muud, neto |
- Aastas
- Kvartalis
2022 | 2021 | 2020 | 2019 | 2018 | |
---|---|---|---|---|---|
Käibevarad kokku | 67.29 | 92.853 | 118.003 | 20.787 | 31.208 |
Raha ja lühiajalised investeeringud | 63.724 | 90.765 | 116.737 | 20.051 | 28.458 |
Raha ja ekvivalendid | 37.142 | 90.765 | 116.737 | 20.051 | 28.258 |
Lühiajalised investeeringud | 26.582 | 0.2 | |||
Prepaid Expenses | 3.388 | 2.088 | 1.266 | 0.736 | 2.75 |
Total Assets | 68.651 | 93.585 | 118.809 | 21.744 | 31.321 |
Property/Plant/Equipment, Total - Net | 0.087 | 0.075 | 0.04 | 0.19 | 0.019 |
Property/Plant/Equipment, Total - Gross | 2.644 | ||||
Accumulated Depreciation, Total | -2.625 | ||||
Intangibles, Net | 0.094 | ||||
Total Current Liabilities | 7.682 | 5.465 | 5.858 | 7.341 | 5.21 |
Accounts Payable | 2.917 | 1.959 | 1.143 | 0.871 | 3.279 |
Accrued Expenses | 4.765 | 3.506 | 3.082 | 2.83 | 0.066 |
Notes Payable/Short Term Debt | 0 | 0 | 0 | 0 | 0 |
Other Current Liabilities, Total | 0 | 1.633 | 3.64 | 1.865 | |
Total Liabilities | 7.682 | 5.465 | 5.858 | 7.432 | 5.21 |
Total Long Term Debt | 0 | 0 | 0 | 0 | 0 |
Total Equity | 60.969 | 88.12 | 112.951 | 14.312 | 26.111 |
Common Stock | 0.057 | 0.049 | 0.049 | 0.015 | 0.024 |
Additional Paid-In Capital | 219.203 | 202.201 | 195.699 | 79.869 | 626.142 |
Retained Earnings (Accumulated Deficit) | -158.3 | -114.13 | -82.797 | -65.572 | -600.055 |
Total Liabilities & Shareholders’ Equity | 68.651 | 93.585 | 118.809 | 21.744 | 31.321 |
Total Common Shares Outstanding | 57.464 | 49.429 | 48.802 | 15.387 | 24.0518 |
Other Long Term Assets, Total | 1.274 | 0.657 | 0.766 | 0.767 | |
Other Liabilities, Total | 0 | 0.091 | |||
Laekumata arved, neto | 0.178 | ||||
Other Equity, Total | 0.009 |
Mar 2023 | Dec 2022 | Sep 2022 | Jun 2022 | Mar 2022 | |
---|---|---|---|---|---|
Käibevarad kokku | 57.917 | 67.29 | 74.79 | 80.98 | 85.066 |
Raha ja lühiajalised investeeringud | 54.317 | 63.724 | 70.628 | 78.9 | 82.159 |
Raha ja ekvivalendid | 11.244 | 37.142 | 70.628 | 78.9 | 82.159 |
Prepaid Expenses | 3.6 | 3.566 | 4.162 | 2.08 | 2.907 |
Total Assets | 58.282 | 68.651 | 76.17 | 81.526 | 85.488 |
Property/Plant/Equipment, Total - Net | 0.05 | 0.087 | 0.122 | 0.157 | 0.031 |
Other Long Term Assets, Total | 0.315 | 1.274 | 1.258 | 0.389 | 0.391 |
Total Current Liabilities | 5.488 | 7.682 | 7.626 | 7.512 | 5.294 |
Accounts Payable | 1.964 | 2.917 | 2.456 | 2.519 | 2.395 |
Accrued Expenses | 3.524 | 4.765 | 5.052 | 4.782 | 2.899 |
Notes Payable/Short Term Debt | 0 | 0 | 0 | 0 | 0 |
Other Current Liabilities, Total | 0.118 | 0.211 | 0 | ||
Total Liabilities | 5.794 | 7.682 | 7.626 | 7.525 | 5.294 |
Total Long Term Debt | 0 | 0 | 0 | 0 | 0 |
Other Liabilities, Total | 0.306 | 0.013 | |||
Total Equity | 52.488 | 60.969 | 68.544 | 74.001 | 80.194 |
Common Stock | 0.059 | 0.057 | 0.056 | 0.052 | 0.049 |
Additional Paid-In Capital | 222.205 | 219.203 | 215.388 | 209.724 | 204.179 |
Retained Earnings (Accumulated Deficit) | -169.787 | -158.3 | -146.9 | -135.775 | -124.034 |
Total Liabilities & Shareholders’ Equity | 58.282 | 68.651 | 76.17 | 81.526 | 85.488 |
Total Common Shares Outstanding | 58.711 | 57.464 | 55.517 | 52.15 | 49.429 |
Lühiajalised investeeringud | 43.073 | 26.582 | |||
Other Equity, Total | 0.011 | 0.009 |
- Aastas
- Kvartalis
2022 | 2021 | 2020 | 2019 | 2018 | |
---|---|---|---|---|---|
Netotulu/algväärtus | -44.17 | -31.333 | -17.225 | -34.188 | -38.418 |
Raha majandustegevusest | -36.704 | -26.589 | -17.495 | -16.746 | -39.346 |
Raha majandustegevusest | 0.046 | ||||
Mittelikviidsed varad | 7.535 | 6.044 | 1.405 | 19.955 | 2.363 |
Muutused tööjõus | -0.069 | -1.3 | -1.675 | -2.513 | -3.337 |
Tulu investeeringutelt | -26.498 | 0 | 16.137 | 27.883 | |
Kapitalikulutused | 0 | ||||
Muud rahavood investeeringutelt, kokku | -26.498 | 0 | 16.137 | 27.883 | |
Rahavood investeeringutelt | 9.579 | 0.617 | 114.181 | 0.015 | 23.905 |
Rahavoogudesse investeerimine | -0.672 | ||||
Aktsiate emiteerimine (tagasiost), neto | 9.579 | 0.617 | 113.88 | 0.015 | 24.577 |
Laenu väljastamine (kustutamine), neto | 0 | 0.301 | |||
Rahaline kogumuutus | -53.623 | -25.972 | 96.686 | -0.594 | 12.442 |
Mar 2023 | Dec 2022 | Sep 2022 | Jun 2022 | Mar 2022 | |
---|---|---|---|---|---|
Net income/Starting Line | -11.487 | -44.17 | -32.77 | -21.645 | -9.904 |
Cash From Operating Activities | -10.969 | -36.704 | -27.702 | -15.736 | -8.606 |
Non-Cash Items | 1.481 | 7.535 | 5.773 | 3.764 | 2.022 |
Changes in Working Capital | -0.963 | -0.069 | -0.705 | 2.145 | -0.724 |
Cash From Financing Activities | 1.119 | 9.579 | 7.565 | 3.871 | 0 |
Issuance (Retirement) of Stock, Net | 1.119 | 9.579 | 7.565 | 3.871 | 0 |
Net Change in Cash | -25.898 | -53.623 | -20.137 | -11.865 | -8.606 |
Issuance (Retirement) of Debt, Net | |||||
Cash From Investing Activities | -16.048 | -26.498 | |||
Other Investing Cash Flow Items, Total | -16.048 | -26.498 |
Investori nimi | Investori liik | Ringluse protsent | Hoitud osakud | Muutus osakutes | Hoidmise kuupäev | Hinnang käibele |
---|---|---|---|---|---|---|
Shanghai Pharmaceutical USA Inc | Corporation | 6.0354 | 3544441 | 0 | 2023-04-27 | |
The Vanguard Group, Inc. | Investment Advisor/Hedge Fund | 4.877 | 2864140 | 0 | 2023-03-31 | LOW |
Millennium Management LLC | Hedge Fund | 2.5466 | 1495549 | 335804 | 2023-03-31 | HIGH |
Medical Strategy GmbH | Investment Advisor | 1.9641 | 1153451 | 0 | 2023-01-31 | LOW |
BlackRock Institutional Trust Company, N.A. | Investment Advisor | 1.5275 | 897060 | -100702 | 2023-03-31 | LOW |
Hale (David F) | Individual Investor | 1.2456 | 731498 | 125000 | 2023-04-27 | LOW |
Kennedy Capital Management, Inc. | Investment Advisor | 1.0001 | 587366 | 319124 | 2023-03-31 | |
Breitmeyer James B | Individual Investor | 0.8365 | 491277 | 50776 | 2023-04-27 | LOW |
Quantum Private Wealth, LLC | Investment Advisor | 0.779 | 457487 | -6869 | 2023-03-31 | LOW |
Geode Capital Management, L.L.C. | Investment Advisor/Hedge Fund | 0.7076 | 415584 | 0 | 2023-03-31 | LOW |
Brighton Jones LLC | Investment Advisor | 0.5712 | 335437 | 1562 | 2023-03-31 | LOW |
Renaissance Technologies LLC | Hedge Fund | 0.4344 | 255100 | 13300 | 2023-03-31 | HIGH |
Two Sigma Investments, LP | Hedge Fund | 0.3596 | 211184 | -233332 | 2023-03-31 | HIGH |
ACT Capital Management, L.L.C. | Hedge Fund | 0.3576 | 210000 | 0 | 2022-09-30 | MED |
LPL Financial LLC | Investment Advisor | 0.292 | 171459 | 37000 | 2023-03-31 | LOW |
Acadian Asset Management LLC | Investment Advisor/Hedge Fund | 0.282 | 165611 | -56497 | 2023-03-31 | MED |
State Street Global Advisors (US) | Investment Advisor/Hedge Fund | 0.2748 | 161401 | 0 | 2023-03-31 | LOW |
Dowling & Yahnke, LLC | Investment Advisor | 0.2562 | 150464 | 0 | 2022-09-30 | LOW |
CI Private Wealth, LLC | Investment Advisor | 0.2562 | 150464 | 0 | 2023-03-31 | |
IEQ Capital LLC | Investment Advisor | 0.2459 | 144434 | 0 | 2023-03-31 | LOW |
Miks valida Capital.com? Meie numbrid räägivad iseenda eest.
Capital.com Group530K+
Kauplejad
87K+
Igakuiste aktiivsete klientide arv
$46M+
Igakuine investeerimise maht
$31M+
Igakuiselt välja võetud
Kauplemiskalkulaator
Arvutage oma hüpoteetiline võit/kaotus, kui oleksite avanud CFD-tehingu ühel kindlal kuupäeval (valige kuupäev) ja sulgenud teisel kuupäeval (valige kuupäev).
- 1:1
- 20
- 100
- 500
- 1000
- 10000
GTX Inc Company profile
Ettevõttest GTX Inc
Oncternal Therapeutics, Inc. on kliinilise faasi biofarmatseutiline ettevõte. Ettevõte keskendub onkoloogiliste ravimeetodite arendamisele selliste vähihaigete patsientide raviks, kellel on kriitilised rahuldamata meditsiinilised vajadused. Ettevõtte tootekandidaatide hulka kuuluvad Zilovertamab, ONCT-808, ONCT-534 ja ONCT-216. Zilovertamab on uuritav humaniseeritud monoklonaalne antikeha, mis on kavandatud inhibeerima retseptori türosiini kinaasi sarnast harvaesinevat retseptorit 1 (ROR1), kasvufaktori retseptorit, mida ekspresseerivad paljud kasvajad ja mis aktiveerib kasvajate proliferatsiooni, invasiivsuse ja ravimiresistentsuse suurenemise radasid, ning seondub ROR1 spetsiifilise funktsionaalselt olulise epitoobi külge. ONCT-808 on autoloogne kimeerilise antigeeni retseptori (CAR-T) ravi, mis on suunatud ROR1-le hematoloogiliste pahaloomuliste haiguste ja soliidtuumorite raviks. ONCT-534 on kahetoimeline androgeeni retseptori inhibiitor (DAARI) kaugelearenenud kastratsiooniresistentse eesnäärmevähi (CRPC) ja muude androgeeni retseptoriga (AR) seotud haiguste raviks.
Industry: | Biotechnology & Medical Research (NEC) |
12230 El Camino Real
Suite 230
SAN DIEGO
CALIFORNIA 92130
US
Tuluaruanne
- Annual
- Quarterly
Teised on vaadanud veel
Kas otsite jätkuvalt vahendajat, keda saab usaldada?
Ühinege 530,000+ kauplejaga üle kogu maailma, kes valisid kauplemiseks veebisaidi Capital.com